Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume & ASP by Product & Application The global human microbiome market will witness a robust CAGR of 31.08%, valued at $115.42 million in 2021, expected to appreciate and reach $1318.72 million by 2030, confirms Strategic Market Research. North America comprehensively dominated the entire market and is expected to continue its sheer domination over the forecasted time period. The human microbiota, according to NCBI, is made up of 10-100 trillion symbiotic microbial cells that live in each person's gut and play a significant role in the betterment of human health. Drivers - Growth of Industry-Institute Partnerships and the Rising Trend of Self-cleaning Technologies Key factors that promote the growth of the human microbiome market are an Increase in Industry-Institute Partnerships, increasing incidence of lifestyle diseases, rising focus on human Microbiome therapies, growing technological advancements in metagenomics, and next-generation sequencing. Other crucial determinants include the continuing trend of self-cleaning technologies and increased usage of Lightweight materials to improve safety and efficiency. Restraints - Limited Infrastructure and Higher Costs High cost, limited infrastructural facilities, and inadequate research on the human microbiome are some of the restraining factors of this industry. Key Trends and Opportunities An upsurge in the public-private funding for target research activities, a growing geriatric population base, and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the industry in the future. Market Analysis Of Different Segments Covered in the Report Based on Product Probiotics Prebiotics Medical Foods Drugs Based on Application Therapeutics Diagnostics Based on Disease Type Infectious Metabolic Endocrine Regional Coverage Analysis North America United States of America Canada Rest of North America Europe United Kingdom Germany France Italy Spain Russia Rest of Europe Asia-Pacific Japan China India Australia South Korea Singapore Rest of Asia-Pacific LAMEA Brazil Argentina South Africa Saudi Arabia United Arab Emirates Rest of LAMEA Segments Analysis & Insights By Product, the Drugs category accounted for the largest product segment. The growing number of human microbiome-based therapeutic products in clinical trials and increased funding to develop microbiome-based medications can be linked to this segment's substantial share. By Application, the Diagnostics sector is poised to have the fastest growth rate due to scientific and technological innovations in human genome mapping and the emergence of omics technologies. By Region, North America dominates the market because of the strong foundation of healthcare facilities and increased investment from major players in the growth of advanced technologies. Asia-Pacific is projected to witness the fastest growth rate due to better rising awareness, the increase in government initiatives, a rise in medical tourism, and R&D in the region. Human Microbiome Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 115.42 Million The revenue forecast in 2030 USD 1318.72 Million Growth rate CAGR of approximately 31.8% The base year for estimation 2021 Unit USD Million, CAGR (2021 - 2030) Segmentation By Product, By Disease Type, By Application, By Region By Product Probiotics, Prebiotics, Medical Foods, Drugs. By Disease Type Infectious, Metabolic, Endocrine. By Application Therapeutics, Diagnostics. By Region Asia Pacific, North America, Europe, LAMEA Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles Yakult Honsha Co., AOBiome, Enterome Biosciences SA, Metabiomics Corp. (BioSpherex LLC), Microbiome Therapeutics LLC, Osel, Inc., Rebiotix, Inc., Second Genome, Seres Therapeutics, Synthetic Biologics, Inc., Vedanta Biosciences, 4D Pharma, Du Pont De Nemours and Co., Ferring Pharmaceuticals. Human Microbiome Market Competitive Landscape Analysis The industry report has the competitive landscape analysis, which details the most significant competitors operating in the global market. The comparison is based on overall revenue generation, market initiatives, company overview, R&D investment, production analysis, value chain optimization, market share financials, company strengths and weaknesses, global presence, production capacity, production sites and facilities, market potential, and other variables. Yakult Honsha Co. AOBiome Enterome Biosciences SA Metabiomics Corp. (BioSpherex LLC) Microbiome Therapeutics LLC Osel, Inc. Rebiotix, Inc. Second Genome Seres Therapeutics Synthetic Biologics, Inc. Vedanta Biosciences 4D Pharma Du Pont De Nemours and Co. Ferring Pharmaceuticals Recent Developments In February 2022, 4D Pharma received FDA approval for two Live Biotherapeutics (LBPs) to treat Parkinson's disease, MRx0005, and MRx0029. In December 2021, the fecal microbiome data from 4D pharma's successful phase 2 study of the Blautix medication was released. Irritable bowel syndrome (IBS) with constipation and diarrhoea is commonly treated with this. Thus, it is expected to cater to a ton of future growth opportunities for the market. Various Devices that Key Market Leaders Develop Product Function Key players Yakult Probiotic health drink Rich in good bacteria helps in fighting infections. Yakult Honsha Co. Danisco Probiotic cultures for digestion Du Pont De Nemours and Co. MRx0005 Used as Biotherapeutic Products (LBPs) for the treatment of Parkinson’s disease 4D Pharma rAD-IFN/Syn3 Patients with non-muscle invasive bladder cancer may benefit from a novel gene-based therapy. Ferring Pharmaceuticals Frequently Asked Question About This Report How big is the global human microbiome market? The global human microbiome market size was $115.42 Mn in 2021 and is predicted to reach $1318.72 Mn by 2030 with a CAGR of 31.08%. What is the growth rate of the Global Human Microbiome Market Forecast? The market is projected to grow with a CAGR of 31.08 %. What is the estimated value of the Global Human Microbiome Market Forecast? Human Microbiome Market Size will grow to USD 1318.72 Mn by 2030 What is the human microbiome market all about? The genes present inside diverse microorganisms discovered in the genetic picture, or metagenome of humans, are referred to as the human microbiome. Microorganisms like bacteria, fungi, archaea, microbiota, protozoans, non-living viruses, protists, viruses and numerous single-celled creatures are present in the biliary tract, conjunctiva, gastrointestinal tract, Lung, mammary glands, Nasal cavity, Oral cavity, oral mucosa, ovarian follicles, Placenta, skin, saliva, seminal fluid, Uterus, Vagina, Urethra and bladder. How much does the human microbiome cost? There is a wide range of products microbiome companies make. For Yakult Fat-Free Probiotic Drink, 2.7 Fl Oz costs $2.84 for five packets (21.0 ¢/fl oz). What will be the compound annual growth rate (CAGR) of the market during the forecast period and the trend of the Human Microbiome Modulators Market? The Global Human Microbiome Market share is poised to grow with a CAGR of 31.08 %. However, The Global Human Microbiome Modulators Market is poised to grow with a CAGR of 16.5%. What is the human microbiome market growth? The global human microbiome market is expected to grow at a compound annual growth rate (CAGR) of 31.8% from 2021 to 2030 to reach USD 1318.72 million by 2030. How big is the microbiome market? The market size of the Global Human Microbiome Market was valued at USD 115.42 Mn in 2021. . 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Human Microbiome Market 4.2.1 Global Market, 2021-2030 (USD Million) 4.3 By Product 4.3.1 Global Market, By Product, 2021-2030 (USD Million) 4.4 By Application 4.4.1 Global Market, By Application, 2021-2030 (USD Million) 4.5 By Disease Type 4.5.1 Global Market, By Disease Type, 2021-2030 (USD Million) 4.7 By Region 4.7.1 Global Market, By Region, 2021-2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 Market PEST analysis 4.9.2 Market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. By Product Analysis 5.11.1. Trends in By Product (2014-2020) 5.11.2. Trends in By Product (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Collaborative Robot Manufacturing Sites, Area Served, Product Payload 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Probiotics 7.3.1. Probiotics market, 2021-2030 (USD Million) 7.4. Prebiotics 7.4.1. Prebiotics market, 2021-2030 (USD Million) 7.5 Medical Foods 7.5.1. Medical Foods market, 2021-2030 (USD Million) 7.6. Drugs 7.6.1. Drugs market, 2021-2030 (USD Million) 8. Global Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Therapeutics 8.3.1. Therapeutics Market, 2021-2030 (USD Million) 8.4. Diagnostics 8.4.1. Diagnostics Market, 2021-2030 (USD Million) 9. Global Market: By Disease Type Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Infectious 9.3.1. Infectious market, 2021-2030 (USD Million) 9.4. Metabolic 9.4.1. Metabolic market, 2021-2030 (USD Million) 9.5. Endocrine 9.5.1. Endocrine market, 2021-2030 (USD Million) 10. Global Market: Regional Outlook 10.1 North America 10.1.1. North America Market, By Product, 2021-2030 (USD Million) 10.1.2. North America Market, By Application, 2021-2030 (USD Million) 10.1.3. North America Market, By Disease Type, 2021-2030 (USD Million) 10.1.4. North America Market, By Country, 2021-2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S. Market, By Product, 2021-2030 (USD Million) 10.1.4.1.2. U.S. Market, By Application, 2021-2030 (USD Million) 10.1.4.1.3. U.S. Market, By Disease Type, 2021-2030 (USD Million) 10.1.4.1.3. U.S. Market, By Country, 2021-2030 (USD Million) 10.1.4.2. Canada 10.1.4.2.1. Canada Market, By Product, 2021-2030 (USD Million) 10.1.4.2.2. Canada Market, By Application, 2021-2030 (USD Million) 10.1.4.2.3. Canada Market, By Disease Type, 2021-2030 (USD Million) 10.1.4.1.3. Canada. Market, By Country, 2021-2030 (USD Million) 10.2. Europe 10.2.1. Europe Market, By Product, 2021-2030 (USD Million) 10.2.2. Europe Market, By Application, 2021-2030 (USD Million) 10.2.3. Europe Market, By Disease Type, 2021-2030 (USD Million) 10.2.4. Europe Market, By country, 2021-2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. Market, By Product, 2021-2030 (USD Million) 10.2.4.1.2. U.K. Market, By Application, 2021-2030 (USD Million) 10.2.4.1.3. U.K. Market, By Disease Type, 2021-2030 (USD Million) 10.2.4. U.K. Market, By country, 2021-2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany Market, By Product, 2021-2030 (USD Million) 10.2.4.2.2. Germany Market, By Application, 2021-2030 (USD Million) 10.2.4.2.3. Germany Market, By Disease Type, 2021-2030 (USD Million) 10.2.4.2.3 Germany Market, By country, 2021-2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France Market, By Product, 2021-2030 (USD Million) 10.2.4.3.2. France Market, By Application, 2021-2030 (USD Million) 10.2.4.3.3. France Market, By Disease Type, 2021-2030 (USD Million) 10.2.4.2.3 France Market, By country, 2021-2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of Europe Market, By Product, 2021-2030 (USD Million) 10.2.4.4.2. Rest of Europe Market, By Application, 2021-2030 (USD Million) 10.2.4.4.3. Rest of Europe Market, By Disease Type, 2021-2030 (USD Million) 10.2.4.4.4 Rest of Europe Market, By country, 2021-2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific Market, By Product, 2021-2030 (USD Million) 10.3.2. Asia Pacific Market, By Application, 2021-2030 (USD Million) 10.3.3. Asia Pacific Market, By Disease Type, 2021-2030 (USD Million) 10.3.4. Asia Pacific Market, By country, 2021-2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China Market, By Product, 2021-2030 (USD Million) 10.3.4.1.2. China Market, By Application, 2021-2030 (USD Million) 10.3.4.1.3. China Market, By Disease Type, 2021-2030 (USD Million) 10.2.4.4.4 China Market, By country, 2021-2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India Market, By Product, 2021-2030 (USD Million) 10.3.4.2.2. India Market, By Application, 2021-2030 (USD Million) 10.3.4.2.3. India Market, By Disease Type, 2021-2030 (USD Million) 10.2.4.4.4 India Market, By country, 2021-2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan Market, By Product, 2021-2030 (USD Million) 10.3.4.3.2. Japan Market, By Application, 2021-2030 (USD Million) 10.3.4.3.3. Japan Market, By Disease Type, 2021-2030 (USD Million) 10.2.4.4.4 Japan Market, By country, 2021-2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea Market, By Product, 2021-2030 (USD Million) 10.3.4.4.2. South Korea Market, By Application, 2021-2030 (USD Million) 10.3.4.4.3. South Korea Market, By Disease Type, 2021-2030 (USD Million) 10.3.4.4.3. South Korea Market, By country, 2021-2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC Market, By Type, 2021-2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC Market, By Application, 2021-2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC Market, By Disease Type, 2021-2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC Market, By country , 2021-2030 (USD Million) 10.4. Latin America 10.4.1. Latin America Market, By Product, 2021-2030 (USD Million) 10.4.2. Latin America Market, By Application, 2021-2030 (USD Million) 10.4.3. Latin America Market, By Disease Type, 2021-2030 (USD Million) 10.4.4. Latin America Market, By country, 2021-2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil Market, By Product, 2021-2030 (USD Million) 10.4.4.1.2. Brazil Market, By Application, 2021-2030 (USD Million) 10.4.4.1.3. Brazil Market, By Disease Type, 2021-2030 (USD Million) 10.4.4.1.3. Brazil Market, By Country, 2021-2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico Market, By Product, 2021-2030 (USD Million) 10.4.4.2.2. Mexico Market, By Application, 2021-2030 (USD Million) 10.4.4.2.3. Mexico Market, By Disease Type, 2021-2030 (USD Million) 10.4.4.2.3. Mexico Market, By Country, 2021-2030 (USD Million) 10.4.4.3. Rest of the Latin America 10.4.4.3.1. Rest of the Latin America Market, By Product, 2021-2030 (USD Million) 10.4.4.3.2. Rest of the Latin America Market, By Application, 2021-2030 (USD Million) 10.4.4.3.3. Rest of the Latin America Market, By Disease Type, 2021-2030 (USD Million) 10.4.4.3.3. Rest of the Latin America Market, By Country, 2021-2030 (USD Million) 10.5. MEA 10.5.1. MEA Market, By Product, 2021-2030 (USD Million) 10.5.2. MEA Market, By Application, 2021-2030 (USD Million) 10.5.3. MEA Market, By Disease Type, 2021-2030 (USD Million) 10.5.4. MEA Market, by Country , 2021-2030 (USD Million) 11. Competitive Landscape 11.1 Yakult Honsha Co. 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. Product Portfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2. AOBiome 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. Enterome Biosciences SA 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. Metabiomics Corp. (BioSpherex LLC) 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. Microbiome Therapeutics LLC 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. Osel, Inc. . 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. Rebiotix, Inc. 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Second Genome 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. Seres Therapeutics 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. Synthetic Biologics, Inc 11.10.1. Company overview 11.10.2. Financial performance 11.10.3. Product Portfolio Analysis 11.10.4. Business Strategy & Recent Development 11.11. Vedanta Biosciences 11.11.1. Company overview 11.11.2. Financial performance 11.11.3. Product Portfolio Analysis 11.11.4. Business Strategy & Recent Development 11.12. 4D Pharma 11.12.1. Company overview 11.12.2. Financial performance 11.12.3. Product Portfolio Analysis 11.12.4. Business Strategy & Recent Development 11.13. Du Pont De Nemours and Co. 11.13.1. Company overview 11.13.2. Financial performance 11.13.3. Product Portfolio Analysis 11.13.4. Business Strategy & Recent Development 11.14. Ferring Pharmaceuticals 11.14.1. Company overview 11.14.2. Financial performance 11.14.3. Product Portfolio Analysis 11.14.4. Business Strategy & Recent Development List of Tables (64 Tables) TABLE 1. Market, By Product, 2021-2030 (USD Million) TABLE 2. Market FOR Probiotics, BY REGION, 2021-2030 (USD Million) TABLE 3. Market FOR Prebiotics, BY REGION, 2021-2030 (USD Million) TABLE 4. Market FOR Medical Foods, BY REGION, 2021-2030 (USD Million) TABLE 5. Market FOR Drugs, BY REGION, 2021-2030 (USD Million) TABLE 10. Market, By Application, 2021-2030 (USD Million) TABLE 11. NORTH AMERICA Market FOR Therapeutics, BY COUNTRY, 2021-2030 (USD Million) TABLE 12. NORTH AMERICA Market FOR Diagnostics,BY COUNTRY, 2021-2030 (USD Million) TABLE 13. NORTH AMERICA Market Radial Access, By Disease Type, 2021-2030 (USD Million) TABLE 14. EUROPE Market, FOR Infectious By Application, 2021-2030 (USD Million) TABLE 15. NORTH AMERICA Market FOR Metabolic, BY COUNTRY, 2021-2030 (USD Million) TABLE 16. NORTH AMERICA Market FOR Endocrine, BY COUNTRY, 2021-2030 (USD Million) TABLE 16. ASIA-PACIFIC Market, By Product, 2021-2030 (USD Million) TABLE 17. ASIA-PACIFIC Market, By Application, 2021-2030 (USD Million) TABLE 18. ASIA-PACIFIC Market, By Disease Type, 2021-2030 (USD Million) TABLE 19. ASIA-PACIFIC Market, BY END-USER, 2021-2030 (USD Million) TABLE 20. LAMEA Market, By Product, 2021-2030 (USD Million) TABLE 21. LAMEA Market, By Application, 2021-2030 (USD Million) TABLE 22. LAMEA Market, By Disease Type, 2021-2030 (USD Million) TABLE 23. LAMEA Market, BY END-USER, 2021-2030 (USD Million) TABLE 24. Terumo Corporation: COMPANY SNAPSHOT TABLE 25. Terumo Corporation: OPERATING SEGMENTS TABLE 26. Yakult Honsha Co.: COMPANY SNAPSHOT TABLE 27. Yakult Honsha Co.: OPERATING SEGMENTS TABLE 28. Enterome Biosciences SA.: COMPANY SNAPSHOT TABLE 29. Enterome Biosciences SA.: OPERATING SEGMENTS TABLE 30. Metabiomics Corp. (BioSpherex LLC): COMPANY SNAPSHOT TABLE 31. Metabiomics Corp. (BioSpherex LLC): OPERATING SEGMENTS TABLE 32. Microbiome Therapeutics LLC: COMPANY SNAPSHOT TABLE 33. Microbiome Therapeutics LLC: OPERATING SEGMENTS TABLE 34. Osel, Inc.: COMPANY SNAPSHOT TABLE 35. Osel, Inc.: OPERATING SEGMENTS TABLE 36. Rebiotix, Inc.: COMPANY SNAPSHOT TABLE 37. Rebiotix, Inc.: OPERATING SEGMENTS TABLE 38. Second Genome: COMPANY SNAPSHOT TABLE 39. Second Genome: OPERATING SEGMENTS TABLE 40. Seres Therapeutics.: COMPANY SNAPSHOT TABLE 41. Seres Therapeutics.: OPERATING SEGMENTS TABLE 42. Synthetic Biologics, Inc: COMPANY SNAPSHOT TABLE 43. Synthetic Biologics, Inc: OPERATING SEGMENTS TABLE 44. Vedanta Biosciences: COMPANY SNAPSHOT TABLE 45. Vedanta Biosciences: OPERATING SEGMENTS TABLE 46. 4D Pharma: COMPANY SNAPSHOT TABLE 47. 4D Pharma OPERATING SEGMENTS TABLE 48. Du Pont De Nemours and Co.: COMPANY SNAPSHOT TABLE 49. Du Pont De Nemours and Co.OPERATING SEGMENTS TABLE 50. Ferring Pharmaceuticals.: COMPANY SNAPSHOT TABLE 51. Ferring Pharmaceuticals.OPERATING SEGMENTS List of Figures (22 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research By Product Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 16 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Market, By Application, 2019 vs. 2025 (USD Million) Figure 9 Market Share, By Disease Type, 2019 vs. 2025 (USD Million) Figure 10 Geographical Snapshot of the Market Figure 11 Drugs to Witness Higher CAGR in the Market for , By Product during Forecast Period. Figure 12 Diagnostics to Witness Higher CAGR in the Market for By Application during Forecast Period. Figure 13 North American to Witness Higher CAGR in the Market for By Region Segment during Forecast Period. Figure 14 Market: Drivers, Restraints, Opportunities, and Challenges Figure 15 North America: Market Snapshot Figure 16 Asia Pacific: Market Snapshot Figure 17 Vendor Dive: Evaluation Overview